CoChat

Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Doxorubicin is a strong inducer of immunogenic cell death (ICD), but it is ineffective in P-glycoprotein (Pgp)-expressing cells. Indeed, Pgp effluxes doxorubicin and impairs the immunesensitizing functions of calreticulin (CRT), an “eat-me” signal mediating ICD. It is unknown if classical Pgp inhibitors, designed to reverse chemoresistance, may restore ICD. We addressed this question by using Pgp-expressing cancer cells, treated with Tariquidar, a clinically approved Pgp inhibitor, and R-3 compound, a N,N-bis(alkanol)amine aryl ester derivative with the same potency of Tariquidar as Pgp inhibitor. In Pgp-expressing/doxorubicin-resistant cells, Tariquidar and R-3 increased doxorubicin accumulation and toxicity, reduced Pgp activity, and increased CRT translocation and ATP and HMGB1 release. Unexpectedly, only R-3 promoted phagocytosis by dendritic cells and activation of antitumor CD8+T-lymphocytes. Although Tariquidar did not alter the amount of Pgp present on cell surface, R-3 promoted Pgp internalization and ubiquitination, disrupting its interaction with CRT. Pgp knock-out restores doxorubicin-induced ICD in MDA-MB-231/DX cells that recapitulated the phenotype of R-3-treated cells. Our work demonstrates that plasma membrane-associated Pgp prevents a complete ICD notwithstanding the release of ATP and HMGB1, and the exposure of CRT. Pharmacological compounds reducing Pgp activity and amount may act as promising chemo- and immunesensitizing agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9041033

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 R-3 increases doxorubicin intracellular content by inhibiting Pgp activity. (a) Immunoblotting of the indicated proteins in human colon cancer HT29 cells, non-small cell lung cancer A549 cells, triple-negative breast cancer MDA-MB-231 cells, and in their doxorubicin (DX)-resistant variants. Tubulin was used as control of equal protein loading. The image is representative of 1 out of 3 experiments. (b) Cells were incubated for 3 h in medium containing 5 μM doxorubicin (dox), in the absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3. Intracellular doxorubicin content was measured fluorimetrically in duplicates (n = 3). Data are means ± SD. * p < 0.005: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (c) Cells were grown for 24 h in the absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3. Pgp ATPase activity was measured spectrophotometrically on membrane extracts of DX variants. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells. (d) MDA-MB-231/DX cells were grown in the absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3 for 24 h, then incubated for 20 min with increasing concentrations (0–50 μM) of doxorubicin (dox). The procedure was repeated on a second series of dishes, incubated in the same experimental conditions and analyzed after 10 min. Data are means ± SD (n = 3). The rate of doxorubicin efflux (dc/dt) was plotted versus the intracellular concentration of the drug.
Figure 1 R-3 increases doxorubicin intracellular content by inhibiting Pgp activity. (a) Immunoblotting of the indicated proteins in human colon cancer HT29 cells, non-small cell lung cancer A549 cells, triple-negative breast cancer MDA-MB-231 cells, and in their doxorubicin (DX)-resistant variants. Tubulin was used as control of equal protein loading. The image is representative of 1 out of 3 experiments. (b) Cells were incubated for 3 h in medium containing 5 μM doxorubicin (dox), in the absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3. Intracellular doxorubicin content was measured fluorimetrically in duplicates (n = 3). Data are means ± SD. * p < 0.005: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (c) Cells were grown for 24 h in the absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3. Pgp ATPase activity was measured spectrophotometrically on membrane extracts of DX variants. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells. (d) MDA-MB-231/DX cells were grown in the absence (ctrl) or presence of 75 nM Tariquidar (Tar) or 75 nM R-3 for 24 h, then incubated for 20 min with increasing concentrations (0–50 μM) of doxorubicin (dox). The procedure was repeated on a second series of dishes, incubated in the same experimental conditions and analyzed after 10 min. Data are means ± SD (n = 3). The rate of doxorubicin efflux (dc/dt) was plotted versus the intracellular concentration of the drug.CC BY · PubMed Central
Figure 2 R-3 increases doxorubicin-induced apoptosis and cytotoxicity in Pgp-expressing cells. (a) Human colon cancer HT29 cells, non-small cell lung cancer A549 cells, triple-negative breast cancer MDA-MB-231 cells, and their doxorubicin (DX)-resistant variants were incubated 24 h (a) or 48 h (b), in fresh medium (ctrl), without inhibitors (- in) or with 75 nM Tariquidar (Tar) or 75 nM R-3. When indicated, 5 μM doxorubicin (dox) was added. (a) Activity of caspase 3 was measured fluorimetrically in duplicates (n = 3). Data are means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (b) Cell viability was measured by a chemiluminescence-based assay in quadruplicates. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.05: DX cells vs. parental cells.
Figure 2 R-3 increases doxorubicin-induced apoptosis and cytotoxicity in Pgp-expressing cells. (a) Human colon cancer HT29 cells, non-small cell lung cancer A549 cells, triple-negative breast cancer MDA-MB-231 cells, and their doxorubicin (DX)-resistant variants were incubated 24 h (a) or 48 h (b), in fresh medium (ctrl), without inhibitors (- in) or with 75 nM Tariquidar (Tar) or 75 nM R-3. When indicated, 5 μM doxorubicin (dox) was added. (a) Activity of caspase 3 was measured fluorimetrically in duplicates (n = 3). Data are means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (b) Cell viability was measured by a chemiluminescence-based assay in quadruplicates. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.05: DX cells vs. parental cells.CC BY · PubMed Central
Figure 3 R-3 but not Tariquidar rescues the immunogenic cell death induced by doxorubicin in Pgp-expressing cells. (a) Human triple-negative breast cancer MDA-MB-231 cells and their doxorubicin (DX)-resistant variant were incubated 6 h (a and b) or 24 h (c–f), in fresh medium (ctrl) or in medium containing 5 μM doxorubicin (dox). Cells were grown without inhibitors (- in), with 75 nM Tariquidar (Tar) or 75 nM R-3. (a) Dot plots representative of surface calreticulin (CRT), performed by flow cytometry in duplicate (n = 3). Numbers represent the percentage of cells/quadrant. Cut-off for positivity was fixed at 102. SSC: side-scatter. The image is representative of 1 out of 3 experiments. (b) Release of extracellular ATP, measured by a chemiluminescence-based assay in duplicates (n = 3). Data are means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (c) Release of extracellular HMGB1, measured by ELISA in duplicates (n = 3). Data are means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (d) After the treatments indicated in panel (c), tumor cells were stained with FITC-PKH2 dye and DCs were stained with an anti-PE-HLA-DR antibody. Tumor cells were co-incubated with DCs for 24 h. Double-stained cells were counted by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (e) T-lymphocytes were co-cultured with DCs after phagocytosis, and then incubated 24 h with MDA-MB-231 or MDA-MB-231/DX cells. The percentage of CD8+CD107a+T-cells was measured by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (f) IFN-γ concentration was measured in the supernatants of T-lymphocytes, treated as indicated in (e), by ELISA in duplicates. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells.
Figure 3 R-3 but not Tariquidar rescues the immunogenic cell death induced by doxorubicin in Pgp-expressing cells. (a) Human triple-negative breast cancer MDA-MB-231 cells and their doxorubicin (DX)-resistant variant were incubated 6 h (a and b) or 24 h (c–f), in fresh medium (ctrl) or in medium containing 5 μM doxorubicin (dox). Cells were grown without inhibitors (- in), with 75 nM Tariquidar (Tar) or 75 nM R-3. (a) Dot plots representative of surface calreticulin (CRT), performed by flow cytometry in duplicate (n = 3). Numbers represent the percentage of cells/quadrant. Cut-off for positivity was fixed at 102. SSC: side-scatter. The image is representative of 1 out of 3 experiments. (b) Release of extracellular ATP, measured by a chemiluminescence-based assay in duplicates (n = 3). Data are means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (c) Release of extracellular HMGB1, measured by ELISA in duplicates (n = 3). Data are means ± SD. * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (d) After the treatments indicated in panel (c), tumor cells were stained with FITC-PKH2 dye and DCs were stained with an anti-PE-HLA-DR antibody. Tumor cells were co-incubated with DCs for 24 h. Double-stained cells were counted by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (e) T-lymphocytes were co-cultured with DCs after phagocytosis, and then incubated 24 h with MDA-MB-231 or MDA-MB-231/DX cells. The percentage of CD8+CD107a+T-cells was measured by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells. (f) IFN-γ concentration was measured in the supernatants of T-lymphocytes, treated as indicated in (e), by ELISA in duplicates. Data are means ± SD (n = 3). * p < 0.001: treated cells vs. respective ctrl cells; ° p < 0.001: DX cells vs. parental cells.CC BY · PubMed Central
Figure 4 R-3 disrupts Pgp-calreticulin interaction, favoring the internalization and ubiquitination of Pgp. Human triple-negative breast cancer MDA-MB-231 cells and their doxorubicin (DX)-resistant variant were incubated for 24 h in fresh medium (ctrl) or in medium containing 5 μM doxorubicin (dox). When indicated, 75 nM Tariquidar (Tar) or 75 nM R-3 were added. (a) Proximity ligation assay between Pgp and calreticulin. Blank: cells incubated without primary antibodies. Blue signal: nuclear staining (DAPI). Green signal: Pgp/calreticulin interaction. The image is representative of 1 out of 3 experiments. A minimum of 5 fields/experiment was examined. Bar: 10 μm (10× ocular lens; 63× objective lens). (b) Plasma membrane extracts were immunoblotted and decorated to detect Pgp or CRT, or immuno-precipitated (IP) with an anti-CRT antibody, then immunoblotted (IB) with an anti-Pgp antibody. no Ab: MDA-MB-231 and MDA-MB-231/DX samples treated with doxorubicin, immuno-precipitated without antibodies. An aliquot of the extracts before the immunoprecipitation was probed with an anti-pancadherin antibody, as control of equal protein loading. The figure is representative of 1 out of 3 experiments. (c) MDA-MB-231/DX cells were incubated 24 h with 75 nM R-3. During the last 18 h, cells were transfected with an expression vector for GFP-conjugated Rab5a, to label early endosomes. Subsequently, cells were labeled with an anti-PE-Pgp antibody. Immunofluorescence detection of Pgp co-localized with Rab5a was achieved by confocal microscope analysis. The image is representative of 1 out of 3 experiments. A minimum of 5 fields/experiment was examined. Bar: 10 μm (10× ocular lens; 60× objective lens). (d) Whole cell extracts of MDA-MB-231/DX cells were immunoprecipitated with an anti-Pgp antibody, then immunoblotted for ubiquitin (UQ). An aliquot of the extracts before the immunoprecipitation was probed with an anti-Pgp antibody, as index of the total amount of Pgp immunoprecipitated in each sample. The figure is representative of 1 out of 3 experiments.
Figure 4 R-3 disrupts Pgp-calreticulin interaction, favoring the internalization and ubiquitination of Pgp. Human triple-negative breast cancer MDA-MB-231 cells and their doxorubicin (DX)-resistant variant were incubated for 24 h in fresh medium (ctrl) or in medium containing 5 μM doxorubicin (dox). When indicated, 75 nM Tariquidar (Tar) or 75 nM R-3 were added. (a) Proximity ligation assay between Pgp and calreticulin. Blank: cells incubated without primary antibodies. Blue signal: nuclear staining (DAPI). Green signal: Pgp/calreticulin interaction. The image is representative of 1 out of 3 experiments. A minimum of 5 fields/experiment was examined. Bar: 10 μm (10× ocular lens; 63× objective lens). (b) Plasma membrane extracts were immunoblotted and decorated to detect Pgp or CRT, or immuno-precipitated (IP) with an anti-CRT antibody, then immunoblotted (IB) with an anti-Pgp antibody. no Ab: MDA-MB-231 and MDA-MB-231/DX samples treated with doxorubicin, immuno-precipitated without antibodies. An aliquot of the extracts before the immunoprecipitation was probed with an anti-pancadherin antibody, as control of equal protein loading. The figure is representative of 1 out of 3 experiments. (c) MDA-MB-231/DX cells were incubated 24 h with 75 nM R-3. During the last 18 h, cells were transfected with an expression vector for GFP-conjugated Rab5a, to label early endosomes. Subsequently, cells were labeled with an anti-PE-Pgp antibody. Immunofluorescence detection of Pgp co-localized with Rab5a was achieved by confocal microscope analysis. The image is representative of 1 out of 3 experiments. A minimum of 5 fields/experiment was examined. Bar: 10 μm (10× ocular lens; 60× objective lens). (d) Whole cell extracts of MDA-MB-231/DX cells were immunoprecipitated with an anti-Pgp antibody, then immunoblotted for ubiquitin (UQ). An aliquot of the extracts before the immunoprecipitation was probed with an anti-Pgp antibody, as index of the total amount of Pgp immunoprecipitated in each sample. The figure is representative of 1 out of 3 experiments.CC BY · PubMed Central
Figure 5 Pgp knock-out restores doxorubicin-induced immunogenic cell death. MDA-MB-231/DX cells (wild-type, wt) were transduced with a non-targeting vector (scrambled vector; scr) or with two CRISPR pCas Pgp-targeting vectors (KO#1, KO#2). Cells were grown in fresh medium (- dox) or in the presence of 5 μM doxorubicin (+ dox), for 6 h (B,C) or 24 h (D–F). (A). Pgp immunoblotting in whole cell extracts. Tubulin was used as control of equal protein loading. The image is representative of 1 out of 3 experiments. (B). Dot plots representative of surface calreticulin (CRT), performed by flow cytometry in duplicates (n = 3). Numbers represent the percentage of cells/quadrants. Cut-off for positivity was fixed at 102. SSC: side-scatter. The image is representative of 1 out of 3 experiments. (C). Release of extracellular ATP, measured by a chemiluminescence-based assay in duplicates (n = 3). Data are means ± SD. * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells. (D) Release of extracellular HMGB1, measured by ELISA in duplicates (n = 3). Data are means ± SD. * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs.-- dox cells. (E) After the treatment indicated in (D), tumor cells were stained with FITC-PKH2 dye, DCs were stained with an anti-PE-HLA-DR antibody. Tumor cells were co-incubated with DCs for 24 h. Double-stained cells were counted by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells. (F) T-lymphocytes were co-cultured with DCs after phagocytosis, then incubated 24 h with scr- or KO-cells. The percentage of CD8+ CD107a+ T-cells was measured by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells. (G) IFN-γ concentration was measured in the supernatants of T-lymphocytes, treated as indicated in (F), by ELISA in duplicates. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells.
Figure 5 Pgp knock-out restores doxorubicin-induced immunogenic cell death. MDA-MB-231/DX cells (wild-type, wt) were transduced with a non-targeting vector (scrambled vector; scr) or with two CRISPR pCas Pgp-targeting vectors (KO#1, KO#2). Cells were grown in fresh medium (- dox) or in the presence of 5 μM doxorubicin (+ dox), for 6 h (B,C) or 24 h (D–F). (A). Pgp immunoblotting in whole cell extracts. Tubulin was used as control of equal protein loading. The image is representative of 1 out of 3 experiments. (B). Dot plots representative of surface calreticulin (CRT), performed by flow cytometry in duplicates (n = 3). Numbers represent the percentage of cells/quadrants. Cut-off for positivity was fixed at 102. SSC: side-scatter. The image is representative of 1 out of 3 experiments. (C). Release of extracellular ATP, measured by a chemiluminescence-based assay in duplicates (n = 3). Data are means ± SD. * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells. (D) Release of extracellular HMGB1, measured by ELISA in duplicates (n = 3). Data are means ± SD. * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs.-- dox cells. (E) After the treatment indicated in (D), tumor cells were stained with FITC-PKH2 dye, DCs were stained with an anti-PE-HLA-DR antibody. Tumor cells were co-incubated with DCs for 24 h. Double-stained cells were counted by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells. (F) T-lymphocytes were co-cultured with DCs after phagocytosis, then incubated 24 h with scr- or KO-cells. The percentage of CD8+ CD107a+ T-cells was measured by flow cytometry. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells. (G) IFN-γ concentration was measured in the supernatants of T-lymphocytes, treated as indicated in (F), by ELISA in duplicates. Data are means ± SD (n = 3). * p < 0.001: KO-cells vs. scr-cells; ° p < 0.001: + dox cells vs. - dox cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 47 references

Cited by

See all 42

Metadata

Authors
Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C.
Affiliations
  • University of Turin (IT)
  • University of Florence (IT)
  • University of Bari Aldo Moro (IT)
Corresponding author
Riganti, Chiara
Venue
Cells
Publisher
MDPI AG
Published
2020-04-22
Volume
9
Issue
4
Pages
1033
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3019388022
Cited by
41
References
47
Citations by year
2026: 5 · 2025: 5 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4
FWCI
1.99
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
Funders
Associazione Italiana per la Ricerca sul Cancro (IG21408)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
P-glycoprotein inhibitors, immunogenic cell death, doxorubicin resistance, tariquidar, calreticulin, ubiquitination, dendritic cell phagocytosis, CD8+ T cells, HMGB1, ATP release, chemoresistance reversal
MeSH terms
Immunogenic Cell Death, Doxorubicin, Endocytosis, Esters, Humans, Kinetics, Quinolines, Apoptosis, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Calreticulin, Cell Line, Tumor, Ubiquitination, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death. https://app.cochat.ai/papers/10.3390/cells9041033
The paper
Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C. (2020). Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death. Cells. https://doi.org/10.3390/cells9041033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.